Biotech company CSL has appointed Dr Paul McKenzie as its Chief Executive Officer (CEO) and Managing Director.
Dr McKenzie is currently serving as CSL’s Chief Operating Officer (COO) and will immediately join the Board of Directors as an Executive Director and will become CEO and Managing Director on March 6, 2023.
Dr McKenzie has more than 30 years of leadership experience in the global biotechnology space.
Prior to joining CSL, he was Executive Vice President of Pharmaceutical Operations & Technology at Biogen.
Dr McKenzie also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.
CSL Chair, Dr Brian McNamee said:
“Paul McKenzie is a patient-focused global leader with a demonstrated track record of leading complex organisations and delivering outstanding business results.
“With his deep understanding of CSL’s strategy, culture and operations, Paul is well positioned to lead CSL to its next level of sustainable growth for our shareholders and the patients we serve around the world.”
CSL’s portfolio of lifesaving medicines include treatments for haemophilia and immune deficiencies, vaccines to prevent influenza and therapies in iron deficiency, dialysis and nephrology.
Dr McKenzie said:
“CSL’s promise to save people’s lives through science has long distinguished our company.
“I am excited, honoured and humbled for the opportunity to continue building CSL’s legacy following the strong foundation established by Paul Perreault over the last decade.
“I look forward to continuing our momentum and engaging closely with the Board, our leadership team, 30,000 colleagues, and other stakeholders to serve patients and public health around the world.
“We will continue focusing on executing our 2030 strategy, investing in innovation, and continue achieving sustainable and profitable growth.”
